The pharmacological treatment of COVID-19. Conference of Peruvian American Medical Socity (PAMS)

Descripción del Articulo

The pharmacological treatment of COVID-19 has changed a lot during the pandemic. Hydroxychloroquine is not used anymore due to the lack of clinical efficacy. Ivermectin, a medication applied widely in Peru, is not recommended because the scientific evidence to support its use is insufficient. To dat...

Descripción completa

Detalles Bibliográficos
Autor: Gonzales-Zamora, Jose Armando
Formato: artículo
Fecha de Publicación:2021
Institución:Fundación Instituto Hipólito Unanue
Repositorio:Diagnóstico
Lenguaje:español
OAI Identifier:oai:revistadiagnostico.fihu.org.pe:article/237
Enlace del recurso:https://revistadiagnostico.fihu.org.pe/index.php/diagnostico/article/view/237
Nivel de acceso:acceso abierto
Materia:COVID-19
tratamiento
Remdesivir, corticoides
Tocilizumab
anticoagulación
treatment
Remdesivir
corticosteroids
anticoagulation
id REVFIHU_0138aeda3cf4ebab98e28e1c93510d89
oai_identifier_str oai:revistadiagnostico.fihu.org.pe:article/237
network_acronym_str REVFIHU
network_name_str Diagnóstico
repository_id_str
spelling The pharmacological treatment of COVID-19. Conference of Peruvian American Medical Socity (PAMS)Tratamiento farmacológico de COVID-19: Conferencia de la Peruvian American Medical Society (PAMS)Gonzales-Zamora, Jose Armando COVID-19tratamientoRemdesivir, corticoidesTocilizumabanticoagulaciónCOVID-19treatmentRemdesivircorticosteroidsTocilizumabanticoagulationThe pharmacological treatment of COVID-19 has changed a lot during the pandemic. Hydroxychloroquine is not used anymore due to the lack of clinical efficacy. Ivermectin, a medication applied widely in Peru, is not recommended because the scientific evidence to support its use is insufficient. To date, the treatment of hospitalized patients is based in Remdesivir and corticosteroids, and it is only symptomatic without empiric antibiotics in the ambulatory setting. The use of Tocilizumab is still controversial due to the contradictory results of the clinical trials. Although there is probably a higher frequency of thrombotic events in COVID-19, therapeutic anticoagulation is not recommended.El tratamiento farmacológico de COVID-19 ha cambiado mucho durante la pandemia. Medicamentos como la hidroxicloroquina dejaron de utilizarse ya que se demostró que carecían de eficacia clínica. Ivermectina, un medicamento empleado mucho en Perú, carece de evidencia científica suficiente que permita su recomendación. A la fecha, el tratamiento de pacientes hospitalizados se basa en Remdesivir y corticoides; y el de pacientes ambulatorios es solo sintomático, no recomendándose tampoco el uso empírico de antibióticos. El uso de Tocilizumab es todavía controversial ya que los resultados de los ensayos clínicos son contradictorias. A pesar de la frecuencia más alta de eventos trombóticos en COVID-19, no se recomienda en la actualidad la anticoagulación terapéutica empírica.Fundación Instituto Hipólito Unanue2021-01-04info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://revistadiagnostico.fihu.org.pe/index.php/diagnostico/article/view/23710.33734/diagnostico.v59i3.237Diagnóstico; Vol. 59 No. 3 (2020); 141-144Diagnostico; Vol. 59 Núm. 3 (2020); 141-1441018-28882709-795110.33734/diagnostico.v59i3reponame:Diagnósticoinstname:Fundación Instituto Hipólito Unanueinstacron:FIHUspahttps://revistadiagnostico.fihu.org.pe/index.php/diagnostico/article/view/237/241Derechos de autor 2021 Jose Armando Gonzales-Zamorainfo:eu-repo/semantics/openAccessoai:revistadiagnostico.fihu.org.pe:article/2372021-06-04T17:54:59Z
dc.title.none.fl_str_mv The pharmacological treatment of COVID-19. Conference of Peruvian American Medical Socity (PAMS)
Tratamiento farmacológico de COVID-19: Conferencia de la Peruvian American Medical Society (PAMS)
title The pharmacological treatment of COVID-19. Conference of Peruvian American Medical Socity (PAMS)
spellingShingle The pharmacological treatment of COVID-19. Conference of Peruvian American Medical Socity (PAMS)
Gonzales-Zamora, Jose Armando
COVID-19
tratamiento
Remdesivir, corticoides
Tocilizumab
anticoagulación
COVID-19
treatment
Remdesivir
corticosteroids
Tocilizumab
anticoagulation
title_short The pharmacological treatment of COVID-19. Conference of Peruvian American Medical Socity (PAMS)
title_full The pharmacological treatment of COVID-19. Conference of Peruvian American Medical Socity (PAMS)
title_fullStr The pharmacological treatment of COVID-19. Conference of Peruvian American Medical Socity (PAMS)
title_full_unstemmed The pharmacological treatment of COVID-19. Conference of Peruvian American Medical Socity (PAMS)
title_sort The pharmacological treatment of COVID-19. Conference of Peruvian American Medical Socity (PAMS)
dc.creator.none.fl_str_mv Gonzales-Zamora, Jose Armando
author Gonzales-Zamora, Jose Armando
author_facet Gonzales-Zamora, Jose Armando
author_role author
dc.subject.none.fl_str_mv COVID-19
tratamiento
Remdesivir, corticoides
Tocilizumab
anticoagulación
COVID-19
treatment
Remdesivir
corticosteroids
Tocilizumab
anticoagulation
topic COVID-19
tratamiento
Remdesivir, corticoides
Tocilizumab
anticoagulación
COVID-19
treatment
Remdesivir
corticosteroids
Tocilizumab
anticoagulation
description The pharmacological treatment of COVID-19 has changed a lot during the pandemic. Hydroxychloroquine is not used anymore due to the lack of clinical efficacy. Ivermectin, a medication applied widely in Peru, is not recommended because the scientific evidence to support its use is insufficient. To date, the treatment of hospitalized patients is based in Remdesivir and corticosteroids, and it is only symptomatic without empiric antibiotics in the ambulatory setting. The use of Tocilizumab is still controversial due to the contradictory results of the clinical trials. Although there is probably a higher frequency of thrombotic events in COVID-19, therapeutic anticoagulation is not recommended.
publishDate 2021
dc.date.none.fl_str_mv 2021-01-04
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://revistadiagnostico.fihu.org.pe/index.php/diagnostico/article/view/237
10.33734/diagnostico.v59i3.237
url https://revistadiagnostico.fihu.org.pe/index.php/diagnostico/article/view/237
identifier_str_mv 10.33734/diagnostico.v59i3.237
dc.language.none.fl_str_mv spa
language spa
dc.relation.none.fl_str_mv https://revistadiagnostico.fihu.org.pe/index.php/diagnostico/article/view/237/241
dc.rights.none.fl_str_mv Derechos de autor 2021 Jose Armando Gonzales-Zamora
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Derechos de autor 2021 Jose Armando Gonzales-Zamora
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Fundación Instituto Hipólito Unanue
publisher.none.fl_str_mv Fundación Instituto Hipólito Unanue
dc.source.none.fl_str_mv Diagnóstico; Vol. 59 No. 3 (2020); 141-144
Diagnostico; Vol. 59 Núm. 3 (2020); 141-144
1018-2888
2709-7951
10.33734/diagnostico.v59i3
reponame:Diagnóstico
instname:Fundación Instituto Hipólito Unanue
instacron:FIHU
instname_str Fundación Instituto Hipólito Unanue
instacron_str FIHU
institution FIHU
reponame_str Diagnóstico
collection Diagnóstico
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1846524447704481792
score 13.088951
The pharmacological treatment of COVID-19. Conference of Peruvian American Medical Socity (PAMS)
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).

Ejemplares Similares